Effects of Huperzine A in Treatment of Moderate to Severe TBI
Department of Defense
Huperzine A, an acetylcholinesterase inhibitor with neuroprotective qualities, is suspected to aid in the improvement of memory functioning in patients who have suffered a traumatic brain injury. With the use of Huperzine A in moderate to severe TBI patients, this trial aims to determine whether Huperzine A, as compared with placebo, would have an effect on cognitive and functional deficits after TBI. Additionally, we aim to determine whether use of Huperzine A in these patients can change brain activity (as indexed by EEG and Transcranial Magnetic Stimulation – TMS), and reduce prevalence/frequency of post-traumatic seizures. Finally, we aim to evaluate the safety of Huperzine A in this population as compared with placebo.
To evaluate the effects of Huperzine A on memory function randomized, double-blind, placebo-controlled clinical trial with moderate to severe TBI patients, ages 18-50. With the potential outcome of this Huperzine A trial improving memory functioning, this trial would demonstrate an innovative measure to improve a patient’s quality of life post-trauma, and provide a new medical resource for TBI-induced cognitive deficits.
This study is in collaboration with the Spaulding Rehabiliation Hospital Neuromodulation Laboratory and several other Spaulding Rehabilitation Hospital researchers.